Market capitalization | $702.24m |
Enterprise Value | $747.08m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.01 |
P/S ratio (TTM) P/S ratio | 2.83 |
P/B ratio (TTM) P/B ratio | 119.09 |
Revenue growth (TTM) Revenue growth | 34.43% |
Revenue (TTM) Revenue | $248.33m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Evolus, Inc. forecast:
7 Analysts have issued a Evolus, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 248 248 |
34%
34%
|
|
Gross Profit | 168 168 |
35%
35%
|
|
EBITDA | -26 -26 |
25%
25%
|
EBIT (Operating Income) EBIT | -32 -32 |
21%
21%
|
Net Profit | -55 -55 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.
Head office | United States |
CEO | David Moatazedi |
Employees | 273 |
Founded | 2012 |
Website | www.evolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.